Advertisement

Day after DCGI's nod, SII seeks inclusion of Covovax in COVID-19 immunisation programme

Serum Institute of India has written to the Centre seeking the inclusion of Covovax in the national COVID-19 vaccination programme in the interest of public health, official sources said on Wednesday.

Advertisement
|Jun 29, 2022, 19:28:57 IST

New Delhi: A day after India's drug regulator approved Covovax for restricted emergency use in children aged 7 to 11 years, the vaccine maker Serum Institute has written to the Centre seeking its inclusion in the national COVID-19 vaccination programme in the interest of public health, official sources said on Wednesday.

Advertisement

In a letter to the Union health ministry, Prakash Kumar Singh, Director, Government and Regulatory Affairs at Serum Institute of India (SII) stated that Covovax is highly immunogenic with more than 98 percent seroconversion in 7 to less than 12 years age group. Also, the vaccine is safe, effective and well tolerated in this age group, an official source said.

indiaMore from India

According to the letter, the firm is also receiving requests from various sections of the society pan India to make vaccine available in government and private hospitals in view of increasing COVID-19 infections.

"Even employees of our firm, who have relentlessly worked on this life-saving vaccine, are requesting to us to provide this life-saving vaccine for their children soon," Singh is learnt to have mentioned in the letter.

Advertisement

The approval by the Drugs Controller General of India (DCGI) on Wednesday came after the subject expert committee on COVID-19 of the CSDCO last week recommended granting emergency use authorisation to Covovax for the age group of 7 to 11 years.

''The SEC last week deliberated on the EUA application of SII and recommended granting emergency use authorisation for Covovax for children aged 7 to 11 years,'' an official source said.

The expert panel in its last meeting in April had sought more data from the Pune-based firm over the application.

The DCGI had approved Covovax for restricted use in emergency situations in adults on 28 December and in the 12 to 17 years age group subject to certain conditions on 9 March.

Read all the Latest News, Trending News, Cricket News, Bollywood News,

India News and Entertainment News here. Follow us on Facebook, Twitter and Instagram.

Handpicked stories, in your inbox
Global stories. Indian perspective. Zero noise.
No Spam. Unsubscribe Any Time.
First Published:Jun 29, 2022, 19:28:57 IST
Advertisement
Advertisement
Trending Stories

'From make in India to launch from India': Skyroot COO on why Vikram-1 could change India’s space sector

Skyroot Aerospace’s successful Vikram-1 mission marks a major milestone for India’s private space sector, as the country seeks to shift from “Make in India” to “Launch from India” and compete in the global commercial satellite launch market
8 min read
Advertisement
Advertisement
Up Next